36 results on '"Adilbay D"'
Search Results
2. Epigenetic markers-based breast cancer early detection method development
- Author
-
GONCHAROVA, T., primary, KAIDAROVA, D., additional, OMARBAYEVA, N., additional, ASKANDIROVA, A., additional, ORAZGALIYEVA, M., additional, ADILBAY, D., additional, CHEISHVILI, D., additional, VAISHEVA, F., additional, and SZYF, M., additional
- Published
- 2020
- Full Text
- View/download PDF
3. Aggressive giant dermatofibrosarcoma protuberance occurring in the parotid gland: Clinical case
- Author
-
ADILBAEV, G., primary, ADILBAY, D., additional, KHOZHAMKUL, F., additional, TOIYNBEKOVA, S., additional, and AKHMETOV, D., additional
- Published
- 2020
- Full Text
- View/download PDF
4. Early diagnostic of lung cancer based on methylation of mononuclear cell fraction: Method development
- Author
-
GONCHAROVA, T. G., primary, KAIDAROVA, D. R., additional, KADYRBAYEVA, R. E., additional, ORAZGALIEVA, M. G., additional, ADILBAY, D. G., additional, CHEISHVILI, D., additional, VAISHEVA, F., additional, and SZYF, M., additional
- Published
- 2020
- Full Text
- View/download PDF
5. 380P Immediate results HPV-induced cancer of the mouth and oropharynx in Kazakhstan
- Author
-
Adilbayev, G., primary, Kydyrbayeva, G., additional, Shipilova, V., additional, Sadyk, Z., additional, and Adilbay, D., additional
- Published
- 2016
- Full Text
- View/download PDF
6. O2. Phase II study of concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced squamous cell carcinoma of the oral cavity
- Author
-
Adilbaev, G.-B., primary, Kidirbaeva, G., additional, Savhatova, A.-D., additional, Turesheva, A.-O., additional, and Adilbay, D.-G., additional
- Published
- 2011
- Full Text
- View/download PDF
7. S29. Management of oral & oropharyngeal cancers in ex-Soviet states
- Author
-
Adilbaev, G., primary and Adilbay, D., additional
- Published
- 2011
- Full Text
- View/download PDF
8. Concurrent chemoradiotherapy of patients with locally advanced squamous cell carcinoma of the oral cavity (stage III, IV)
- Author
-
Adilbay, D. G., primary, Adilbaev, G. B., additional, and Ahmetov, D. N., additional
- Published
- 2009
- Full Text
- View/download PDF
9. Intra-arterial chemotherapy using docetaxel and cisplatin + RT with radiomodification in combined treatment of patients with locally advanced SCC of the oral cavity
- Author
-
Adilbay, D. G., primary, Adilbayev, G. B., additional, Ahmetov, D. N., additional, and Kydirbaeva, G. Z., additional
- Published
- 2007
- Full Text
- View/download PDF
10. P63 Intra-arterial chemotherapy in combined treatment of patients with SCC of the oral cavity (stage III, IV)
- Author
-
Adilbayev, G., primary, Shipilova, V., additional, Zhanuzakovna, G., additional, Kaibarov, M., additional, Ahmetov, D., additional, Kim, G., additional, Adilbay, D., additional, and Kidirbayeva, G., additional
- Published
- 2007
- Full Text
- View/download PDF
11. Intra-arterial chemotherapy with docetaxel and cysplatin in combined treatment of patients with locally advanced squamouse cell head and neck cancer (SCHNC)
- Author
-
Adilbayev, G., primary, Adilbay, D., additional, Kim, G., additional, and Ahmetov, D., additional
- Published
- 2006
- Full Text
- View/download PDF
12. Skull base surgery for malignant tumors: The 2nd international collaborative study (1995-2015).
- Author
-
Shah JP, Levyn H, Valero C, Adilbay D, Eagan A, Zheng J, Gonen M, Cohen M, Patel S, Ganly I, Pai P, Castelnuovo P, Gao FJ, Piazza C, Nicolai P, Panizza B, Bowman J, Barnett C, Kowalski LP, Toledo R, Fliss DM, DeAlmeida J, Witterick I, Herman P, Fontanella W, Aniceto GS, Hosal S, Ozer S, Iyer S, Harvey R, Leemans CR, Hendrickx JJ, Figari M, Boccalatte L, Nibu KI, Clarke P, Rennie C, Ming ZY, Cernea C, Goncalves S, Schlosser R, Dias F, Sargi Z, Ahmed S, Golusinski W, Kim SH, Su SY, Raza SM, DeMonte F, and Hanna E
- Subjects
- Humans, Middle Aged, Male, Female, Aged, Adult, Retrospective Studies, Endoscopy, International Cooperation, Prognosis, Treatment Outcome, Neurosurgical Procedures methods, Skull Base Neoplasms surgery, Skull Base Neoplasms mortality, Skull Base Neoplasms pathology
- Abstract
Background: The current study presents the effort of a global collaborative group to review the management and outcomes of malignant tumors of the skull base worldwide., Patients and Methods: A total of 28 institutions contributed data on 3061 patients. Analysis evaluated clinical variables, survival outcomes, and multivariable factors associated with outcomes., Results: The median age was 56 years (IQR 44-67). The open surgical approach was used in 55% (n = 1680) of cases, endoscopic resection was performed in 36% (n = 1087), and the combined approach in 9.6% (n = 294). With a median follow-up of 7.1 years, the 5-year OS DSS and RFS were 65%, 71.7% and 53%, respectively. On multivariable analysis, older age, comorbidities, histology, dural/intracranial involvement, positive margins, advanced stage, and primary site were independent prognostic factors for OS, DSS, and RFS. Adjuvant RT was a protective prognostic factor., Conclusion: The progress across various disciplines may have contributed to improved OS and DSS in this study compared to previous reports., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
13. The Role of ctDNA and Liquid Biopsy in the Diagnosis and Monitoring of Head and Neck Cancer: Towards Precision Medicine.
- Author
-
Nassar SI, Suk A, Nguyen SA, Adilbay D, Pang J, and Nathan CO
- Abstract
Recent data have shown a continued rise in the worldwide annual incidence and mortality rates of head and neck cancers. The present standard for diagnosis and monitoring for disease recurrence or progression involves clinical examination, imaging, and invasive biopsy techniques of lesions suspected of being malignant. In addition to limitations relating to cost, time, and patient discomfort, these methodologies have inherent inaccuracies for detecting recurrence. In view of these limitations, the analysis of patient bodily fluid samples via liquid biopsy proposes a cost-effective and convenient alternative, which provides insight on the biogenetic and biomolecular underpinnings of oncologic disease processes. The monitoring of biomarkers for head and neck cancer via liquid biopsy, including circulating tumor DNA, circulating tumor cells, and circulating cell-free RNA, has shown clinical utility in the screening, diagnosis, prognostication, and monitoring of patients with various forms of head and neck cancer. The present review will provide an update on the current literature examining the use of liquid biopsy in head and neck cancer care and the clinical applicability of potential biomarkers, with a focus on viral and non-viral circulating tumor DNA. Possible future avenues for research to address specific shortcomings of liquid biopsy will be discussed.
- Published
- 2024
- Full Text
- View/download PDF
14. Outcomes of SMARCB1-deficient sinonasal carcinoma: Largest single-center cross-sectional study.
- Author
-
Woods R, Scholfield D, Axiotakis L, Fitzgerald C, Adilbay D, Cracchiolo J, Patel S, Shah J, Dunn L, Pfister D, Lee N, Dogan S, Ganly I, and Cohen M
- Abstract
Background: We evaluate outcomes of SMARCB1-deficient sinonasal carcinomas in the largest single-institution study., Methods: Retrospective cross-sectional study of patients with SMARCB1-deficient sinonasal carcinoma between 1998 and 2024. Disease-specific survival (DSS) and recurrence-free probability (RFP) at 1 and 5 years were measured by Kaplan-Meier method., Results: There were 47 patients with a median age of 53. Initial pathological diagnosis was altered in 33%. Twelve (34%) patients received neoadjuvant chemotherapy, with one partial response. Curative surgical approach was undertaken in 73%. Definitive chemoradiation was administered in 20%. DSS at 1 and 5 years was 93% and 45%, respectively. RFP at 1 and 5 years was 73% and 33%, respectively. On multivariate analysis, cranial nerve involvement (p = 0.01 for DSS) remained significantly worse for DSS and overall survival., Conclusions: SMARCB1-deficient tumors had limited response to neoadjuvant chemotherapy. Cranial nerve involvement was associated with worse prognosis. Optimal treatment is unclear. Surgery should be offered to patients with resectable disease., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
15. ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment.
- Author
-
Lele SJ, Adilbay D, Lewis E, Pang J, Asarkar AA, and Nathan CO
- Subjects
- Humans, Male, Retrospective Studies, Female, Middle Aged, Aged, Risk Assessment, Sensitivity and Specificity, Neoplasm Recurrence, Local diagnostic imaging, Head and Neck Neoplasms genetics, Head and Neck Neoplasms diagnostic imaging, Head and Neck Neoplasms blood, Circulating Tumor DNA genetics, Circulating Tumor DNA blood, Positron-Emission Tomography, Squamous Cell Carcinoma of Head and Neck diagnostic imaging, Squamous Cell Carcinoma of Head and Neck genetics, Squamous Cell Carcinoma of Head and Neck blood
- Abstract
Objective: Circulating tumor DNA (ctDNA) detection is an emerging technique that identifies minimal residual disease in patients with solid tumors. ctDNA can act as an adjunct method to help overcome the limitations of positron emission tomography (PET) and select patients who are at high risk for recurrence., Study Design: Retrospective Single Institutional Study., Setting: University Hospital Setting., Methods: Twenty-nine patients who underwent definitive treatment for squamous cell carcinoma of the head and neck (HNSCC) from 8/2021 to 01/2023 had ctDNA levels analyzed at 1 to 3, 6, 9, and 12 months after definitive treatment. A personalized, tumor-informed, multiplex polymerase chain reaction (PCR) next-generation sequencing (NGS) assay was used to detect the ctDNA levels. The primary outcome was recurrence-free probability (RFP), and the secondary outcomes were overall survival (OS), sensitivity, specificity, and the test's negative (NPV) and positive predictive values (PPV)., Results: The median age of patients was 65 years (interquartile range: 56-69), with majority being males (n = 22, 76%). The primary sites were larynx (n = 12), oropharynx (n = 10), and oral cavity (n = 6). Posttreatment ctDNA was detected in 7 patients, all of whom had disease recurrence. ctDNA detection after definitive treatment was associated with a higher risk of disease recurrence (hazard ratio: 9.94, 95% confidence interval: 1.56-63.3, P = .015). ctDNA identified recurrence with 100% specificity and 78% sensitivity. The NPV and PPV were 91% and 100%. PET had 78% sensitivity but only 68% specificity with 86% NPV, and 54% PPV., Conclusion: Based on our data, ctDNA can be an excellent adjunct test for posttreatment PET and can help guide physicians in cases where PET results are inconclusive and difficult to interpret., (© 2024 American Academy of Otolaryngology–Head and Neck Surgery Foundation.)
- Published
- 2024
- Full Text
- View/download PDF
16. Outcomes of internal mammary artery perforator flap in head and neck reconstruction: A systematic review.
- Author
-
Vasudevan SS, Rogers B, Adilbay D, Olinde L, Pang J, Nathan CO, and Asarkar AA
- Subjects
- Humans, Head and Neck Neoplasms surgery, Female, Male, Treatment Outcome, Perforator Flap blood supply, Perforator Flap transplantation, Plastic Surgery Procedures methods, Mammary Arteries transplantation, Mammary Arteries surgery
- Abstract
This study aims to evaluate the functional and prognostic outcomes associated with the internal mammary artery perforator (IMAP) flap in various head and neck defect repairs, given the current lack of clarity on its effectiveness. We performed a systematic review of various databases: PubMed, Embase, Scopus, Web of Science, and ScienceDirect using keywords such as "Internal mammary artery perforator flap" and "IMAP." Screening and data extractions were performed by two individual reviewers. Articles were considered eligible if they included sufficient information on IMAP flap features, their applications in the head and neck, and outcomes. From 264 articles analyzed, 24 studies were included for qualitative analysis. Out of which, 125 patients who received internal mammary artery perforator flaps were included. Most of the patients, 103 (88%), received pedicled IMAP flaps, and 22 (12%) received IMAP free flaps. The second internal mammary artery (IMA) was favored as the single perforator (81.5%), with the combination of the first and second IMA being the primary choice for dual perforators (92.5%). IMAP flaps were predominantly single perforator flaps (65%), with 35% being dual perforator flaps. Among various applications, IMAP flaps are commonly employed in the reconstruction of neck defects (25.5%), pharyngocutaneous fistula repair (20.8%), and burn scar contracture restoration (8%). Only seven (5.6%) patients had flap complications, including venous congestion (1.6%), partial necrosis (1.6%), complete necrosis (1.6%), and incision dehiscence (0.8%). Donor sites were predominantly closed by the primary closure (92%). 3.2% of donor sites had minor complications. The average follow-up was 12.6 (IQR: 6-18) months. This systematic review highlights the effectiveness and safety of IMAP flaps in head and neck reconstruction, with positive outcomes and minimal complications., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
17. Noninvasive Diagnostic Method to Objectively Measure Olfaction and Diagnose Smell Disorders by a Molecularly Targeted Fluorescence Imaging Agent.
- Author
-
Adilbay D, Gonzales J, Zazhytska M, Demetrio de Souza Franca P, Roberts S, Viray TD, Artschwager R, Patel S, Kodra A, Overdevest JB, Chow CY, King GF, Jain SK, Ordonez AA, Carroll LS, Lomvardas S, Reiner T, and Pillarsetty N
- Subjects
- Animals, Humans, Optical Imaging methods, Smell, Fluorescent Dyes chemistry, Mice, COVID-19 diagnostic imaging, Male, Olfaction Disorders diagnostic imaging
- Abstract
Despite the recent advances in understanding the mechanisms of olfaction, no tools are currently available to noninvasively identify loss of smell. Because of the substantial increase in patients presenting with coronavirus disease 2019-related loss of smell, the pandemic has highlighted the urgent need to develop quantitative methods. Methods: Our group investigated the use of a novel fluorescent probe named Tsp1a-IR800
P as a tool to diagnose loss of smell. Tsp1a-IR800P targets sodium channel 1.7, which plays a critical role in olfaction by aiding the signal propagation to the olfactory bulb. Results: Intuitively, we have identified that conditions leading to loss of smell, including chronic inflammation and coronavirus disease 2019, correlate with the downregulation of sodium channel 1.7 expression in the olfactory epithelium, both at the transcript and at the protein levels. We demonstrated that lower Tsp1a-IR800P fluorescence emissions significantly correlate with loss of smell in live animals-thus representing a potential tool for its semiquantitative assessment. Currently available methods rely on delayed subjective behavioral studies. Conclusion: This method could aid in significantly improving preclinical and clinical studies by providing a way to objectively diagnose loss of smell and therefore aid the development of therapeutic interventions., (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)- Published
- 2024
- Full Text
- View/download PDF
18. Vocal Cord Function Return After Larynx Preservation is Associated With Recurrence-Free Probability.
- Author
-
Adilbay D, Asarkar AA, Kandula RA, Moore-Medline T, and Nathan CA
- Abstract
Objectives: Vocal cord fixation is one of the main upstaging features of laryngeal cancer. In our previously conducted retrospective study, vocal cord (VC) mobility restoration after chemoradiotherapy was a favorable prognostic variable. In this prospective study, we examined the significance of VC mobility restoration after definitive treatment as a prognostic variable., Methods: In this prospective cohort study, we enrolled 30 patients with squamous cell carcinoma of the larynx with VC impairment/fixation (T2/3, T4a) who underwent definitive chemoradiotherapy with complete response. Video laryngoscopy before and at 3 months after treatment was used to evaluate VC mobility. The primary endpoint of the study was the local recurrence-free probability. Secondary endpoints included recurrence-free probability, disease-specific survival (DSS), and overall survival (OS)., Results: The median age of patients was 62 years (IQR 54-67). The primary subsites were the glottis (n = 13) and supraglottis (n = 14). After treatment, 18 (60%) patients had a full recovery of VC mobility, and 12 (40%) patients' VCs were fixed or impaired. Five-year local recurrence-free probability was worse in the VC-impaired group compared to a group with restored VC mobility (46% vs. 85%, p = 0.012). Recurrence-free probability, OS, and DSS differences were not statistically significant in both groups. VC mobility restoration predicted local recurrence-free probability on univariable analysis (HR 6.15, 95% CI 1.23-30.6)., Conclusion: In this prospective study, we show that the absence of VC mobility restoration is associated with worse local recurrence-free probability after definitive laryngeal preservation treatment. Patients with persistent vocal cord immobility warrant closer follow-up to detect recurrence early., Level of Evidence: III Laryngoscope, 2024., (© 2024 The American Laryngological, Rhinological and Otological Society, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
19. Risk Factors for Complications in Patients Undergoing Temporal Bone Resection and Neck Dissection: Insights From a National Database.
- Author
-
Ordoyne LM, Alvarez I, Borne G, Fabian I, Adilbay D, Kandula RA, Asarkar AA, Nathan CO, Olinde L, and Pang J
- Subjects
- Humans, Female, Male, Risk Factors, Middle Aged, Aged, United States epidemiology, Length of Stay statistics & numerical data, Retrospective Studies, Adult, Neck Dissection adverse effects, Postoperative Complications epidemiology, Temporal Bone surgery, Databases, Factual
- Abstract
Background: Temporal bone resection (TBR) with or without neck dissection (ND) is performed for otologic malignancies with occult or clinical cervical lymph node metastases. To date, characterization of post-operative complications in single institution case series may be non-representative of real-world outcomes. Here, we used data from the National Inpatient Sample (NIS) to comprehensively assess the complications encountered, their frequencies, and to identify underlying risk factors to improve future outcomes., Methods: The population was patients undergoing TBR and ND derived from the NIS between the years of 2017 and 2019. We utilized ICD-10 diagnosis codes to identify patients with post-operative complications, those discharged to non-home facilities (DNHF), and those with increased length of stay (LOS). Multivariable regression was performed to identify significant variables related to the above outcomes., Results: Ninety of 277 patients that underwent LTBR with ND had postoperative complications. Wound complications were the most frequent complication, occurring in 11 (4%) of patients, followed by CSF leak (n = 6; 2.2%), with acute respiratory failure being the most common medical complication (n = 4; 1.4%). Sixteen percent (45/277) were discharged to a facility besides home. Dementia (OR = 7.96; CI
95 3.62-17.48), anemia (OR = 2.39; CI95 1.15-4.99), congestive heart failure (OR = 5.31; CI95 1.82-15.45), COPD (OR = 3.70; CI95 1.35-10.16), and history of prior stroke (OR = 8.50; CI95 1.55-46.68) increased the odds of DNHF. When evaluating LOS (median = 5 days, IQR = 1, 9), anemia (OR = 5.49; CI95 2.86-10.52), and Medicaid insurance (OR = 3.07; CI95 1.06-10.52) were found to increase the LOS., Conclusions: The vast majority of patients undergoing LTBR with ND have no complications and are discharged within a week. Liver disease is a risk factor for medical complications and increased charges. Patients with dementia or a prior stroke are at risk for DNHF, and those with prior anemia are at risk for a wound complication., Lay Summary: This study identified factors related to worse post-operative outcomes in patients undergoing temporal bone resection and neck dissection. Although safe for most patients, an existing diagnosis of liver disease, stroke, dementia, and anemia specifically are at risk for developing negative outcomes., Level of Evidence: 3., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.- Published
- 2024
- Full Text
- View/download PDF
20. A Prospective Double-Blinded Comparison of Reflectance Confocal Microscopy with Conventional Histopathology for In Vivo Assessment in Oral Cancer.
- Author
-
Zanoni DK, Demétrio De Souza França P, Valero C, Peterson G, Ardigo M, Ghossein R, Dusza SW, Matsuura D, Scholfield DW, Adilbay D, Montero PH, Migliacci J, Pillarsetty NVK, Kose K, Ganly I, Rajadhyaksha M, and Patel SG
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Biopsy, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell diagnostic imaging, Carcinoma, Squamous Cell diagnosis, Carcinoma, Squamous Cell surgery, Double-Blind Method, Mouth Mucosa pathology, Mouth Mucosa diagnostic imaging, Prospective Studies, Sensitivity and Specificity, Microscopy, Confocal methods, Mouth Neoplasms pathology, Mouth Neoplasms diagnostic imaging, Mouth Neoplasms diagnosis, Mouth Neoplasms surgery
- Abstract
Purpose: We investigated reflectance confocal microscopy (RCM) as a possible noninvasive approach for the diagnosis of cancer and real-time assessment of surgical margins., Experimental Design: In a phase I study on 20 patients, we established the RCM imaging morphologic features that distinguish oral squamous cell carcinoma (OSCC) from normal tissue with a newly developed intraoral RCM probe. Our subsequent phase II prospective double-blinded study in 60 patients tested the diagnostic accuracy of RCM against histopathology. Five RCM videos from the tumor and five from normal surrounding mucosa were collected on each patient, followed by a 3-mm punch biopsy of the imaged area. An experienced RCM reader, who was blinded to biopsy location and histologic diagnosis, examined the videos from both regions and classified each as "tumor" or "not tumor" based on RCM features established in phase I. Hematoxylin and eosin slides from the biopsies were read by a pathologist who was blinded to RCM results. Using histology as the gold standard, we calculated the sensitivity and specificity of RCM., Results: We report a high agreement between the blinded readers (95% for normal tissue and 81.7% for tumors), high specificity (98.3%) and negative predictive values (96.6%) for normal tissue identification, and high sensitivity (90%) and positive predictive values (88.2%) for tumor detection., Conclusions: RCM imaging is a promising technology for noninvasive in vivo diagnosis of OSCC and for real-time intraoperative evaluation of mucosal surgical margins. Its inherent constraint, however, stems from the diminished capability to evaluate structures located at more substantial depths within the tissue., (©2024 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
21. Na V 1.7 targeted fluorescence imaging agents for nerve identification during intraoperative procedures.
- Author
-
Gonzales J, Adilbay D, de Souza Franca PD, Artschwager R, Chow CY, Viray T, Johnson DS, Jiang Y, Patel SG, Ganly I, Schroeder CI, Lewis JS, King GF, Reiner T, and Pillarsetty N
- Abstract
Surgeries and trauma result in traumatic and iatrogenic nerve damage that can result in a debilitating condition that approximately affects 189 million individuals worldwide. The risk of nerve injury during oncologic surgery is increased due to tumors displacing normal nerve location, blood turbidity, and past surgical procedures, which complicate even an experienced surgeon's ability to precisely locate vital nerves. Unfortunately, there is a glaring absence of contrast agents to assist surgeons in safeguarding vital nerves. To address this unmet clinical need, we leveraged the abundant expression of the voltage-gated sodium channel 1.7 (Na
V 1.7) as an intraoperative marker to access peripheral nerves in vivo , and visualized nerves for surgical guidance using a fluorescently-tagged version of a potent NaV 1.7-targeted peptide, Tsp1a, derived from a Peruvian tarantula. We characterized the expression of NaV 1.7 in sensory and motor peripheral nerves across mouse, primate, and human specimens and demonstrated universal expression. We synthesized and characterized a total of 10 fluorescently labeled Tsp1a-peptide conjugates to delineate nerves. We tested the ability of these peptide-conjugates to specifically accumulate in mouse nerves with a high signal-to-noise ratio in vivo . Using the best-performing candidate, Tsp1a-IR800, we performed thyroidectomies in non-human primates and demonstrated successful demarcation of the recurrent laryngeal and vagus nerves, which are commonly subjected to irreversible damage. The ability of Tsp1a to enhance nerve contrast during surgery provides opportunities to minimize nerve damage and revolutionize standards of care across various surgical specialties., Competing Interests: Competing Interests T.R. and J.S.L are shareholders of Summit Biomedical Imaging, LLC. T.R. is a paid consultant for Theragnostics, Inc. T.R. is now an employee of and a shareholder of Evergreen Theragnostics. All other authors have no conflict to declare. This arrangement has been reviewed and approved by MSK in accordance with its conflict-of-interest policies. P.D.S.M., J.G, J.S.L., T.R., Y.J., and G.F.K. are co-inventors on a US patent describing the Tsp1a peptide.- Published
- 2024
- Full Text
- View/download PDF
22. Chronic heart failure in patients undergoing major head and neck surgery: A hospital-based study.
- Author
-
Alvarez IA, Ordoyne L, Borne G, Fabian I, Adilbay D, Kandula RA, Asarkar A, Nathan CA, and Pang J
- Subjects
- Humans, Retrospective Studies, Comorbidity, Hospitals, Postoperative Complications epidemiology, Hospitalization, Head and Neck Neoplasms complications, Head and Neck Neoplasms surgery
- Abstract
Objective: To investigate the effects of chronic heart failure on various post-operative outcomes in head and neck cancer patients undergoing major cancer surgery., Study Design: For this retrospective cohort study of patients undergoing major head and neck cancer surgery, a sample of 10,002 patients between 2017 and 2019 were identified through the Nationwide Inpatient Sample., Setting: Patients were selected as undergoing major head and neck cancer surgery, defined as laryngectomy, pharyngectomy, glossectomy, neck dissection, mandibulectomy, and maxillectomy, then separated based on pre-surgical diagnosis of chronic heart failure., Methods: The effects of pre-operative chronic heart failure on post-surgical outcomes in these patients were investigated by univariable and multivariable logistic regression using ICD-10 codes and SPSS., Results: A diagnosis of chronic heart failure was observed in 265 patients (2.6 %). Patients with chronic heart failure had more preexisting comorbidities when compared to patients without chronic heart failure (mean ± SD; 4 ± 1 vs. 2 ± 1). Multivariable logistic regression showed that chronic heart failure patients had significantly greater odds of dying during hospitalization (OR 2.86, 95 % CI 1.38-5.91) and experiencing non-routine discharge from admission (OR 1.89, 95 % CI 1.41-2.54) after undergoing major head and neck cancer surgery., Conclusion: Chronic heart failure is associated with greater length of stay and hospital charges among head and neck cancer patients undergoing major head and neck cancer surgeries. Chronic heart failure patients have significantly greater rates of unfavorable post-operative outcomes, including death during hospitalization and non-routine discharge from admission., Competing Interests: Declaration of competing interest The Authors declare that there is no conflict of interest or declarations of interest. No funding to report., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
23. Prevalence, incidence, and mortality rates of breast cancer in Kazakhstan: data from the Unified National Electronic Health System, 2014-2019.
- Author
-
Midlenko A, Mussina K, Zhakhina G, Sakko Y, Rashidova G, Saktashev B, Adilbay D, Shatkovskaya O, and Gaipov A
- Subjects
- Adult, Humans, Female, Middle Aged, Aged, Aged, 80 and over, Incidence, Prevalence, Kazakhstan epidemiology, Mammography, Breast Neoplasms epidemiology
- Abstract
Background: Although there are numerous sources of epidemiologic information on breast cancer in Kazakhstan, none of them have specifically examined the burden of this disease. Therefore, this article aims to provide an overview of the breast cancer prevalence, incidence, mortality, and distribution and changes over time in Kazakhstan based on nationwide large-scale healthcare data from the National Registry in order to encourage more research on the impact of various diseases at the regional and national levels., Methods: The study cohort included all adult women older than 25 years who were diagnosed with breast cancer in any clinical setting of the Republic of Kazakhstan during the period of 2014-2019. The data were extracted from the Unified Nationwide Electronic Health System (UNEHS) to get an overview of descriptive statistics, incidence, prevalence, and mortality rate calculations and the Cox proportional hazards regression model. All survival functions and factors associated with mortality were tested for significance., Results: The cohort population ( n = 55,465) comprised subjects with the age at the diagnosis of breast cancer from 25 to 97 years, with a mean of 55.7 ± 12.0 years. The majority of the study population belonged to the age group 45-59 years, which is 44.8% of the cohort. The all-cause mortality rate of the cohort is 16%. The prevalence rate increased from 30.4 per 10,000 population in 2014 to 50.6 in 2019. The incidence rate varied from 4.5 per 10,000 population in 2015 to 7.3 in 2016. Mortality rates were stable and high in the senile age patients (75-89 years old). Breast cancer mortality was positively associated with women who had been diagnosed with diabetes, HR 1.2 (95% CI, 1.1-2.3), whereas it was negatively associated with arterial hypertension, HR 0.4 (95% CI, 0.4-0.5)., Conclusion: Overall, Kazakhstan is experiencing an increase in the incidence of breast cancer cases, but the mortality rate has started to decline. The switch to population mammography screening could reduce the breast cancer mortality rate. These findings should be utilized to help Kazakhstan determine what cancer control priorities should be utilized, including the need to implement efficient and affordable screening and prevention programs., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Midlenko, Mussina, Zhakhina, Sakko, Rashidova, Saktashev, Adilbay, Shatkovskaya and Gaipov.)
- Published
- 2023
- Full Text
- View/download PDF
24. Circulating Human Papillomavirus DNA in Head and Neck Squamous Cell Carcinoma: Possible Applications and Future Directions.
- Author
-
Adilbay D, Lele S, Pang J, Asarkar A, Calligas J, and Nathan CA
- Abstract
There has been a rising trend in HPV-induced head and neck cancers in the last several decades. This subgroup of squamous cell carcinoma is mostly located in the oropharynx and comprises a subset of patients who are typically younger and without the usual risk factors of smoking and alcohol use. As the prognosis of HPV-induced OPC is more favorable, there is a desire to properly select these patients for de-intensification protocols while identifying individuals who may suffer treatment failure. Here, we describe recent developments in circulating tumor HPV DNA as a marker of HPV-positive oropharyngeal cancer that can potentially be used as a diagnostic tool to stratify patients for de-escalation strategies and to survey for recurrence.
- Published
- 2022
- Full Text
- View/download PDF
25. Non-invasive diagnostic method to objectively measure olfaction and diagnose smell disorders by molecularly targeted fluorescent imaging agent.
- Author
-
Adilbay D, Gonzales J, Zazhytska M, Demetrio de Souza Franca P, Roberts S, Viray T, Artschwager R, Patel S, Kodra A, Overdevest JB, Chow CY, King GF, Jain SK, Ordonez AA, Carroll LS, Reiner T, and Pillarsetty N
- Abstract
The sense of smell (olfaction) is one of the most important senses for animals including humans. Despite significant advances in the understanding mechanism of olfaction, currently, there are no objective non-invasive methods that can identify loss of smell. Covid-19-related loss of smell has highlighted the need to develop methods that can identify loss of olfaction. Voltage-gated sodium channel 1.7 (Na
V 1.7) plays a critical role in olfaction by aiding the signal propagation to the olfactory bulb. We have identified several conditions such as chronic inflammation and viral infections such as Covid-19 that lead to loss of smell correlate with downregulation of NaV 1.7 expression at transcript and protein levels in the olfactory epithelium. Leveraging this knowledge, we have developed a novel fluorescent probe Tsp1a-IR800 that targets NaV 1.7. Using fluorescence imaging we can objectively measure the loss of sense of smell in live animals non-invasively. We also demonstrate that our non-invasive method is semiquantitative because the loss of fluorescence intensity correlates with the level of smell loss. Our results indicate, that our probe Tsp1a-IR800, can objectively diagnose anosmia in animal and human subjects using infrared fluorescence. We believe this method to non-invasively diagnose loss of smell objectively is a significant advancement in relation to current methods that rely on highly subjective behavioral studies and can aid in studying olfaction loss and the development of therapeutic interventions., Competing Interests: Disclosure of Potential Conflicts of Interest S.P. and T.R. are shareholders of Summit Biomedical Imaging, T.R. is now an executive of and shareholder in Novartis AG. J.G., P.D.S.F., G.K. and T.R. are co-inventors on a Tsp1a-related patent application. All other authors have no conflicts to declare.- Published
- 2022
- Full Text
- View/download PDF
26. Well-Differentiated Thyroid Cancer: Who Should Get Postoperative Radiation?
- Author
-
Adilbay D, Yuan A, Romesser PB, Wong RJ, Shah JP, Shaha AR, Tuttle MR, Patel S, Lee NY, and Ganly I
- Subjects
- Aged, Humans, Iodine Radioisotopes therapeutic use, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local radiotherapy, Neoplasm Recurrence, Local surgery, Radiotherapy, Adjuvant, Retrospective Studies, Thyroid Cancer, Papillary, Thyroid Neoplasms pathology, Thyroid Neoplasms radiotherapy, Thyroid Neoplasms surgery
- Abstract
Background: The mainstay of treatment of well-differentiated thyroid cancer (WDTC) is surgery followed by adjuvant radioactive iodine therapy. Postoperative radiation therapy (PORT) is rarely used., Objective: The aim of our study was to report our experience of patients with WDTC who were selected to receive PORT., Materials and Methods: After Institutional Review Board approval, patients who received PORT were identified from a departmental database of 6259 patients with WDTC treated with primary surgery from 1986 to 2015. We carried out propensity matching to compare outcomes with a cohort of patients who did not receive PORT. The main outcome of interest was central neck recurrence-free probability (CNRFP), while secondary outcomes were lateral neck recurrence-free probability (LNRFP), disease-specific survival (DSS), and overall survival (OS)., Results: From 6259 patients, 32 (0.5%) patients with a median age of 65.2 years received PORT. Tall-cell variant papillary thyroid carcinoma was the most common pathology (45%). Patients who received PORT had no difference in CNRFP compared with patients treated without PORT (10-year CNRFP 88% vs. 73%; p = 0.18). Furthermore, patients who received PORT had superior LNRFP (10-year LNRFP 100% vs. 62%; p = 0.001) compared with the no-PORT cohort. Despite this, patients who received PORT had similar DSS (71% PORT vs. 75% no-PORT) and OS (65% PORT vs. 58% no-PORT group) as the no-PORT cohort., Conclusions: Our data show that select patients who received PORT had improved locoregional recurrence-free probability; however, this did not translate into improved DSS and OS. At our institution, we recommend the use of PORT only in highly selected patients with locally advanced primary tumors who are deemed to have a high risk of central neck recurrence for which salvage surgery would result in unacceptable risk to the airway., (© 2022. Society of Surgical Oncology.)
- Published
- 2022
- Full Text
- View/download PDF
27. Outcomes in surgical management of sinonasal malignancy-A single comprehensive cancer center experience.
- Author
-
Adilbay D, Valero C, Fitzgerald C, Yuan A, Mimica X, Gupta P, Wong RJ, Shah JP, Patel SG, Ganly I, and Cohen MA
- Subjects
- Female, Humans, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Melanoma pathology, Melanoma surgery, Paranasal Sinus Neoplasms pathology, Paranasal Sinus Neoplasms surgery
- Abstract
Background: Sinonasal malignancies are a complex and diverse group of tumors. Over the past five decades, treatment advances have changed the management paradigms for these tumors. Our aim was to analyze the outcomes of patients from a comprehensive cancer center., Materials and Methods: We retrospectively assessed 400 patients with sinonasal malignancies treated with surgery at our center between 1973 and 2015. Multiple variables were reviewed to assess the influence on 5-year outcomes., Results: The median age was 56 years (IQR 46.8-68). Two hundred and fifty-nine (65%) were males and 141 (35%) were females. Overall survival (OS) and disease-specific survival (DSS) improved in the last analyzed decade. Orbital invasion, advanced pT-classification and pN-classification, and melanoma histology were associated with poorer outcomes., Conclusion: Treatment outcomes for patients with sinonasal malignancy have improved over time. This is likely multifactorial with advances in surgical technique, adjuvant treatment, and patient selection. pT-classification, pN-classification, orbital invasion, and histology are predictive of survival., (© 2022 Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
28. Follicular and Hurthle Cell Carcinoma: Comparison of Clinicopathological Features and Clinical Outcomes.
- Author
-
Matsuura D, Yuan A, Wang L, Ranganath R, Adilbay D, Harries V, Patel S, Tuttle M, Xu B, Ghossein R, and Ganly I
- Subjects
- Humans, Oxyphil Cells pathology, Prognosis, Retrospective Studies, Adenocarcinoma, Follicular pathology, Carcinoma, Hepatocellular, Liver Neoplasms surgery, Thyroid Neoplasms pathology
- Abstract
Background: Follicular thyroid carcinoma (FTC) and Hurthle cell carcinoma (HCC) are rare and aggressive thyroid cancers with limited published data comparing their outcomes or regarding their subtypes. The aim of this study was to describe clinicopathological features and compare clinical outcomes of patients with FTC and HCC based on the 2017 World Health Organization definition and extent of vascular invasion (VI). Methods: We retrospectively studied 190 patients with HCC and FTC primarily treated with surgery at Memorial Sloan Kettering Cancer Center between 1986 and 2015. Patients were classified as minimally invasive (MI), encapsulated angioinvasive with focal VI (EA-FVI), encapsulated angioinvasive with extensive VI (EA-EVI), and as widely invasive (WI). To compare clinical outcomes, patients were grouped as follows: group 1 = FTC-MI and FTC EA-FVI, group 2 = FTC EA-EVI and FTC-WI, group 3 = HCC-MI and HCC EA-FVI, group 4 = HCC EA-EVI and HCC-WI. Outcomes of interest were overall survival (OS), disease-specific survival (DSS), recurrence-free survival (RFS), locoregional recurrence-free survival (LRRFS), and distant recurrence-free survival (DRFS). Outcomes were determined using the Kaplan-Meier method and compared with log-rank test. Results: Patients with HCC ( n = 111) were more likely to be older than 55 years old (59% vs. 27%, p < 0.001) with a tendency to present with more extensive VI (33% vs. 19%, p = 0.07) compared with FTC ( n = 79). Comparing groups 1, 2, 3, and 4, group 4 patients were more likely to recur (DFS 98%, 93%, 98% vs. 73%, respectively, p = 0.0069). There was no statistically significant difference in OS, DSS LRRFS, or DRFS. Stratified by extent of VI (no, focal, and extensive VI), patients with extensive VI were more likely to recur (RFS 100%, 95%, 77%, p = 0.0025) and had poorer distant control (DRFS: 100%, 95%, 80%, p = 0.022), compared with patients absent or focal VI. Conclusions: Accurate assessment of the extent of VI and tumor phenotype (follicular vs. Hurthle) are essential in identifying patients at higher risk of recurrence.
- Published
- 2022
- Full Text
- View/download PDF
29. Predictors of distant metastases in sinonasal and skull base cancer patients treated with surgery.
- Author
-
Valero C, Adilbay D, Fitzgerald CWR, Yuan A, Mimica X, Gupta P, Wong RJ, Shah JP, Patel SG, Cohen MA, and Ganly I
- Subjects
- Humans, Lymphocytes, Neutrophils, Prognosis, Proportional Hazards Models, Retrospective Studies, Skull Base Neoplasms pathology, Survival Rate, Melanoma surgery, Neoplasm Metastasis diagnosis, Skull Base Neoplasms surgery
- Abstract
Objectives: Sinonasal and skull base tumors comprise a heterogeneous group of malignancies with a significant rate of distant recurrence (DR). The aim of this study was to analyze tumor and host factors, including pretreatment neutrophil-to-lymphocyte ratio (NLR), that predict DR in these patients., Materials and Methods: We retrospectively reviewed sinonasal tumors and/or tumors involving the skull base treated with surgery between 1973 and 2015 (n = 473). We stratified NLR using the top 5 percentile as cutoff. Factors predictive of outcome were determined by Cox proportional hazards model., Results: Most tumors were primary (81%) and 67% had skull base resection. The most common site was the nasal cavity (37%) and the most common histology was squamous cell carcinoma (34%). Most patients presented with advanced primary tumor stage (pT3/T4; 80%) and most had no regional neck disease (pNx/N0; 93%). A total of 104 patients developed DR. The 5-year overall and disease-specific survival for patients who developed DR were 36.4% and 35.8%, compared to 69.0% and 74.9% for patients who did not. Patients with DR had a higher percentage of NLR-high patients compared patients without DR (11% vs 3%, p = .006). In a multivariable analysis, melanoma histology (HR = 5.469, 95% CI 3.171-9.433), pT3/T4 (HR = 2.686, 95% CI 1.150-6.275), pN+ (HR = 6.864, 95% CI 3.450-13.653), and NLR-high (HR = 3.489, 95% CI 1.593-7.639) were independent predictors of DR., Conclusion: Melanoma histology, pT, pN, and high NLR predict DR, suggesting that both tumor and host factors need to be considered. NLR may act as a surrogate marker of the host́s immune system., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
30. Predictors of surgical complications in patients with sinonasal malignancy.
- Author
-
Dodhia S, Fitzgerald CWR, McLean AT, Yuan A, Valero Mayor C, Adilbay D, Mimica X, Gupta P, Cracchiolo JR, Patel S, Wong RJ, Shah J, Ganly I, and Cohen MA
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Male, Middle Aged, Nose Neoplasms pathology, Paranasal Sinus Neoplasms pathology, Postoperative Complications etiology, Prognosis, Prospective Studies, Retrospective Studies, Skull Base Neoplasms pathology, Survival Rate, Young Adult, Nose Neoplasms surgery, Paranasal Sinus Neoplasms surgery, Postoperative Complications pathology, Skull Base Neoplasms surgery, Surgical Procedures, Operative adverse effects
- Abstract
Objectives: Sinonasal and skull base tumors are rare, making it difficult to identify trends in surgical outcome. This study examines complications in a large cohort of patients undergoing surgery for sinonasal malignancy., Methods: Following IRB approval, an institutional database was reviewed to identify patients who underwent surgery for sinonasal or skull base malignancies from 1973 to 2016 at our institution. Charlson comorbidity index score and Clavien-Dindo grade were calculated. The main study endpoint was subgroup analysis of Clavien-Dindo Grade 0, Grades 1-2, and Grades 3-5 complications. An ordinal logistic regression model was constructed to assess the association between comorbidities, demographics, tumor characteristics, and surgical complications., Results: In total, 448 patients met inclusion criteria. Perioperative mortality rate at 30 days was 1.6% (n = 7). The rate of severe complications (Clavien-Dindo 3 or higher) was 13.6% (n = 61). Multivariate analysis using an ordinal logistic regression model showed no association between Charlson comorbidity index score and Clavien-Dindo grade of postoperative complication. Advanced T-stage was significantly associated with complications (p = 0.0014; odds ratio: 3.442 [95% confidence interval: 1.615, 7.338])., Conclusion: Surgery for sinonasal and skull base tumors is safe with a low mortality rate. Advanced T-stage is associated with postoperative complications. These findings have implications for preoperative risk stratification. Key Points Surgery for sinonasal malignancy is safe with a 30 mortality of 1.6% and rate of severe complications of 12.8%. There is no association between patient comorbidity and post operative complication. On multivariate analysis, only advanced T stage was associated with increased rate of surgical complication., (© 2021 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
31. Autoimmune disease and oral squamous cell carcinoma: A systematic review.
- Author
-
Pillai A, Adilbay D, Matsoukas K, Ganly I, and Patel SG
- Subjects
- Humans, Neoplasm Recurrence, Local, Squamous Cell Carcinoma of Head and Neck, Autoimmune Diseases epidemiology, Carcinoma, Squamous Cell epidemiology, Carcinoma, Squamous Cell etiology, Head and Neck Neoplasms, Mouth Neoplasms epidemiology, Mouth Neoplasms etiology
- Abstract
Background: Oral cancer is typically related to environmental carcinogen exposure including tobacco and alcohol. Other less investigated risk factors may be related to a suppressed or dysregulated immune state, and in oral cancer, various levels of immune dysregulation have been found to affect survival and recurrence rates. The rationale for this systematic review was to investigate the possible role that a growing chronic host condition like an autoimmune disease may play in this disease., Methods: A systematic search of the literature was carried out using four electronic databases in order to identify original research of any analytic study design type that investigated the relationship between autoimmune disease and oral cancer. Out of 1,947 identified records, 24 observational studies were included for qualitative synthesis., Results: The studies varied in end points ranging from overall survival (OS), standardized incidence ratio (SIR), and hazard ratio (HR). Due to the heterogenous sampling of studies even within the same study design group, a meta-analysis was not employed. The current state of the literature is varied and heterogenous in both study design and endpoints., Conclusion: Major limitations existed introducing significant bias especially in determining cancer risk such as lack of information surrounding known etiologic risk factors such as alcohol and tobacco consumption. Despite these limitations, a signal was seen between autoimmune disease and oral cancer outcomes and risk. Future studies investigating the relationship between autoimmune disease and oral cancer in a more focused and quantitative manner are therefore needed., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
32. A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer.
- Author
-
Demétrio de Souza França P, Kossatz S, Brand C, Karassawa Zanoni D, Roberts S, Guru N, Adilbay D, Mauguen A, Valero Mayor C, Weber WA, Schöder H, Ghossein RA, Ganly I, Patel SG, and Reiner T
- Subjects
- Fluorescent Dyes, Humans, Poly (ADP-Ribose) Polymerase-1, Carcinoma, Squamous Cell diagnostic imaging, Mouth Neoplasms diagnostic imaging
- Abstract
Background: Visual inspection and biopsy is the current standard of care for oral cancer diagnosis, but is subject to misinterpretation and consequently to misdiagnosis. Topically applied PARPi-FL is a molecularly specific, fluorescent contrast-based approach that may fulfill the unmet need for a simple, in vivo, non-invasive, cost-effective, point-of-care method for the early diagnosis of oral cancer. Here, we present results from a phase I safety and feasibility study on fluorescent, topically applied PARPi-FL. Twelve patients with a histologically proven oral squamous cell carcinoma (OSCC) gargled a PARPi-FL solution for 60 s (15 mL, 100 nM, 250 nM, 500 nM, or 1000 nM), followed by gargling a clearing solution for 60 s. Fluorescence measurements of the lesion and surrounding oral mucosa were taken before PARPi-FL application, after PARPi-FL application, and after clearing. Blood pressure, oxygen levels, clinical chemistry, and CBC were obtained before and after tracer administration., Results: PARPi-FL was well-tolerated by all patients without any safety concerns. When analyzing the fluorescence signal, all malignant lesions showed a significant differential in contrast after administration of PARPi-FL, with the highest increase occurring at the highest dose level (1000 nM), where all patients had a tumor-to-margin fluorescence signal ratio of >3. A clearing step was essential to increase signal specificity, as it clears unbound PARPi-FL trapped in normal anatomical structures. PARPi-FL tumor cell specificity was confirmed by ex vivo tabletop confocal microscopy. We have demonstrated that the fluorescence signal arose from the nuclei of tumor cells, endorsing our macroscopic findings., Conclusions: A PARPi-FL swish & spit solution is a rapid and non-invasive diagnostic tool that preferentially localizes fluorescent contrast to OSCC. This technique holds promise for the early detection of OSCC based on in vivo optical evaluation and targeted biopsy of suspicious lesions in the oral cavity., Trial Registration: Clinicaltrials.gov -NCT03085147, registered on March 21st, 2017., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
33. Bimodal Imaging of Mouse Peripheral Nerves with Chlorin Tracers.
- Author
-
Gonzales J, Hernández-Gil J, Wilson TC, Adilbay D, Cornejo M, Demétrio de Souza Franca P, Guru N, Schroeder CI, King GF, Lewis JS, and Reiner T
- Subjects
- Animals, Antineoplastic Agents adverse effects, Female, Fluorescence, Humans, Mice, Mice, Nude, Peripheral Nervous System Diseases chemically induced, Sciatic Nerve diagnostic imaging, Sciatic Nerve drug effects, Peripheral Nervous System Diseases diagnostic imaging, Porphyrins chemistry
- Abstract
Almost 17 million Americans have a history of cancer, a number expected to reach over 22 million by 2030. Cancer patients often undergo chemotherapy in the form of antineoplastic agents such as cis -platin and paclitaxel. Though effective, these agents can induce debilitating side effects; the most common neurotoxic effect, chemotherapy-induced peripheral neuropathy (CIPN), can endure long after treatment ends. Despite the widespread and chronic nature of the dysfunction, no tools exist to quantitatively measure chemotherapy-induced peripheral neuropathy. Such a tool would not only benefit patients but their stratification could also save significant financial and social costs associated with neuropathic pain. In our first step toward addressing this unmet clinical need, we explored a novel dual approach to localize peripheral nerves: Cerenkov luminescence imaging (CLI) and fluorescence imaging (FI). Our approach revolves around the targeting and imaging of voltage-gated sodium channel subtype Na
V 1.7, highly expressed in peripheral nerves from both harvested human and mouse tissues. For the first time, we show that Hsp1a, a radiolabeled NaV 1.7-selective peptide isolated from Homoeomma spec. Peru, can serve as a targeted vector for delivering a radioactive sensor to the peripheral nervous system. In situ , we observe high signal-to-noise ratios in the sciatic nerves of animals injected with fluorescently labeled Hsp1a and radiolabeled Hsp1a. Moreover, confocal microscopy on fresh nerve tissue shows the same high ratios of fluorescence, corroborating our in vivo results. This study indicates that fluorescently labeled and radiolabeled Hsp1a tracers could be used to identify and demarcate nerves in a clinical setting.- Published
- 2021
- Full Text
- View/download PDF
34. A case of aggressive giant dermatofibrosarcoma protuberance occurring in the parotid gland.
- Author
-
Adilbay D, Khozhamkul F, Toiynbekova S, and Ahmetov D
- Abstract
Introduction: Dermatofibrosarcoma protuberans (DFSP) is a cutaneous malignancy that arises from the dermis and invades deeper tissue. The cellular origin of DFSP is not clear. Evidence supports the cellular origin being fibroblastic, histiocytic, or neuroectodermal., Presentation of Case: A 38 years old, women presented with slow-growing large right parotid mass. A total parotidectomy performed with auriculectomy and reconstruction using ALT flap. Diagnosis confirmed by pathology and immunohistochemistry. Tumor recurred in 10 months, the second surgery with subsequent chemoradiotherapy performed. Patient initially treated with wide resection, 4 cycles of chemotherapy and postoperative radiotherapy 40 Gy, with the recurrence in 10 months. We performed a second surgery followed by radiotherapy. She is disease-free for more than two years under follow-up., Discussion: The main treatment of DFSP is surgical resection with wide negative margins or Moh's surgery. Advanced cases treated with addition of radiotherapy or chemoradiotherapy, but with unclear benefits. In our case, huge tumor located in the parotid region recurred after initial surgery and adjuvant treatment., Conclusion: Clinically, DFSP usually manifest as well circumscribed, slow-growing, smooth, and painless masses. In cases with advanced tumor in parotid region, recurrence may occur despite aggressive initial treatment with wide resection and chemoradiotherapy., (Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
35. HPV infection and P16 expression in oral and oropharyngeal cancer in Kazakhstan.
- Author
-
Adilbay D, Adilbayev G, Kidirbayeva G, Shipilova V, Sadyk Z, Koyanbekova G, Sokolenko E, and Klozar J
- Abstract
Background: Human papillomavirus (HPV) is an important etiologic factor in different cancers of anogenital region and also in a fraction of head and neck cancers (HNC) particularly oropharyngeal tumors. The HPV16 genotype associated with the majority of HPV-related head and neck carcinomas. Th incidence of oropharyngeal cancer is increasing in many countries, and the rate of HPV positive tumors is about 70% in Europe and North America. Little known about the prevalence of HPV in HNC in Central Asia., Methods: It's a prospective analysis of patients with verified oral or oropharyngeal cancer. Sociodemographic and clinical data obtained on admission to treatment. The diagnosis of HPV positivity assessed by both the P16 expression on immunohistochemistry(IHC) and polymerase chain reaction (PCR)with HPV DNA detection and HR HPV type determination., Results: Seventy six patients with oral and oropharyngeal cancer tested for HPV. Forteen cases were positive for HPV by PCR and 15 cases by P16 IHC. Of the 35 oropharyngeal tumors, nine were HPV DNA and p16 IHC positive, giving the rate of 25.7%. Of the 41 oral tumors, five were HPV DNA and six p16 IHC positive, giving the rate of 12.2%., Conclusion: It is the first study mapping prevalence of HPV positivity in oral and oropharyngeal cancer in the Central Asian region. The rate of HPV positivity was higher in oropharyngeal than in oral cancer, the nonsmokers were significantly more frequent in the HPV positive group and HPV 16 was the most frequent type. However, the HPV positivity rates are lower than referred in the western world., Competing Interests: Approval for the study obtained from the local institutional ethics committee and informed consent obtained from all study participants.Not applicable.The authors declare that they have no competing financial or non-financial interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Published
- 2018
- Full Text
- View/download PDF
36. Challenges to effective cancer control in China, India, and Russia.
- Author
-
Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, Fan L, Li J, Chavarri-Guerra Y, Liedke PE, Pramesh CS, Badovinac-Crnjevic T, Sheikine Y, Chen Z, Qiao YL, Shao Z, Wu YL, Fan D, Chow LW, Wang J, Zhang Q, Yu S, Shen G, He J, Purushotham A, Sullivan R, Badwe R, Banavali SD, Nair R, Kumar L, Parikh P, Subramanian S, Chaturvedi P, Iyer S, Shastri SS, Digumarti R, Soto-Perez-de-Celis E, Adilbay D, Semiglazov V, Orlov S, Kaidarova D, Tsimafeyeu I, Tatishchev S, Danishevskiy KD, Hurlbert M, Vail C, St Louis J, and Chan A
- Subjects
- Aged, Aged, 80 and over, Alcoholism epidemiology, Breast Neoplasms diagnosis, China, Colorectal Neoplasms diagnosis, Cultural Characteristics, Early Detection of Cancer trends, Economic Development trends, Environmental Pollution adverse effects, Ethnicity, Female, Health Services economics, Health Services Accessibility trends, Health Workforce trends, Healthcare Disparities trends, Humans, India, Male, Medicine, Chinese Traditional, Middle Aged, Neoplasms prevention & control, Rural Health Services trends, Russia epidemiology, Sexism, Smoking, Social Stigma, Urban Health Services trends, Neoplasms therapy
- Abstract
Cancer is one of the major non-communicable diseases posing a threat to world health. Unfortunately, improvements in socioeconomic conditions are usually associated with increased cancer incidence. In this Commission, we focus on China, India, and Russia, which share rapidly rising cancer incidence and have cancer mortality rates that are nearly twice as high as in the UK or the USA, vast geographies, growing economies, ageing populations, increasingly westernised lifestyles, relatively disenfranchised subpopulations, serious contamination of the environment, and uncontrolled cancer-causing communicable infections. We describe the overall state of health and cancer control in each country and additional specific issues for consideration: for China, access to care, contamination of the environment, and cancer fatalism and traditional medicine; for India, affordability of care, provision of adequate health personnel, and sociocultural barriers to cancer control; and for Russia, monitoring of the burden of cancer, societal attitudes towards cancer prevention, effects of inequitable treatment and access to medicine, and a need for improved international engagement., (Copyright © 2014 Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.